Valuation: Guided Therapeutics Inc

Market Cap 2.8Cr 2.42Cr 2.26Cr 2.08Cr 3.92Cr 266.2Cr 3.97Cr 27Cr 10Cr 133.19Cr 11Cr 10Cr 441.13Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 3.09Cr 2.67Cr 2.49Cr 2.29Cr 4.33Cr 293.55Cr 4.38Cr 29Cr 11Cr 146.88Cr 12Cr 11Cr 486.45Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 76 10/04/2006
Director/Board Member 69 10/11/2016
Director/Board Member 70 01/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
+2.32%+0.24%+23.89%+4.72% 21TCr
+2.51%+1.61%+0.31%-21.89% 14TCr
+1.88%+6.26%-21.34%+21.33% 13TCr
-2.75%+3.69%-54.46%-5.89% 7.11TCr
-0.70%+3.74%+12.28%+11.44% 5.16TCr
+0.62%+9.24%-15.14%-20.39% 5TCr
+1.37%+0.58%+22.82%+11.54% 3.93TCr
+0.99%+5.41%+42.25%+38.06% 3.89TCr
+0.40%+4.55%-21.39%+20.01% 3.22TCr
Average +0.79%+3.19%-1.20%+6.55% 8.43TCr
Weighted average by Cap. +1.28%+1.42%+0.14%+3.28%

Financials

2024 2025
Net sales 7T 6.06T 5.65T 5.2T 9.81T 7L 9.92T 66.41T 26.07T 3L 26.29T 25.71T 11.03L 8L 7L 6L 6L 10.75L 7.29Cr 10.87L 72.77L 28.56L 3.65Cr 28.81L 28.17L 12Cr
Net income -24.17L -20.93L -19.51L -17.95L -33.88L -23Cr -34.26L -2.29Cr -90L -11Cr -90.78L -88.78L -38Cr -31.96L -27.68L -25.8L -23.73L -44.8L -30Cr -45.3L -3.03Cr -1.19Cr -15Cr -1.2Cr -1.17Cr -50Cr
Net Debt 17.71L 15.34L 14.3L 13.15L 24.83L 17Cr 25.1L 1.68Cr 65.95L 8.43Cr 66.52L 65.05L 28Cr 28.76L 24.91L 23.22L 21.36L 40.32L 27Cr 40.77L 2.73Cr 1.07Cr 14Cr 1.08Cr 1.06Cr 45Cr
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-